Compound class:
Synthetic organic
Comment: TBA-354 is a nitroimidazole-based antibacterial compound derived from pretomanid (PA-824) [1]. It has narrow-spectrum activity, inhibiting Mycobacterium tuberculosis and Mycobacterium bovis but not nontuberculous mycobacteria (NTM) or the Gram-positive and Gram-negative bacteria tested [2]. TBA-354 was under clinical development for the treatment of tuberculosis (TB), by the non-profit organisation TB Alliance (www.tballiance.org.za), but was discontinued in 2016 [3].
|
|
Bioactivity Comments |
TBA-354 demonstrates in vitro activity against both replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of pretomanid [2]. The MIC for activity of TBA-354 against replicating M. tuberculosis H37Rv is 0.006 μM [2]. |